Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
2011-01-18
2011-01-18
Mondesi, Robert B (Department: 1645)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C424S093480, C424S257100, C424S258100, C435S069100, C435S252300, C435S442000, C435S471000
Reexamination Certificate
active
07871604
ABSTRACT:
Disclosed is an Environmentally Limited Viability System (ELVS) for microorganisms based on temperature differences between permissive and non-permissive environments. Viability of the microorganisms are limited to the permissive environment by specifically expressing one or more essential genes only in the permissive environment, or expressing one or more lethal genes only in the non-permissive environment. Environmentally Limited Viability Systems are also disclosed involving coordinate expression of a combination of required genes and lethal genes. Microorganisms containing an Environmentally Limited Viability System are useful for release into a permissive environment. Temperature regulated Environmentally Limited Viability Systems are particularly suited for use with recombinant avirulentSalmonellavaccines by limiting their growth to the warmer environment inside the host. Such vaccines can be administered to protect humans or warm-blooded animals against bacterial, viral, mycotic and parasitic pathogens, especially those that colonize on or invade through mucosal surfaces. This antigen delivery system can also be used for expression of gamete-specific antigens to induce immune responses to block fertilization, or to induce immune responses to tumor antigens. In the event that an individual sheds live vaccine into the environment, the presence of the ELVS prevents survival of the vaccine. When environmentally regulated lethal genes are present on an extrachromosomal element and are regulated by chromosomal genes, transfer of the extrachromosomal element to other microorganisms will be limited by unregulated expression of the lethal genes in the recipient microorganism.
REFERENCES:
patent: 4190495 (1980-02-01), Curtiss
patent: 4436815 (1984-03-01), Hershberger et al.
patent: 4506013 (1985-03-01), Hershberger et al.
patent: 4650761 (1987-03-01), Hershberger et al.
patent: 4968619 (1990-11-01), Curtiss, III
patent: 5190931 (1993-03-01), Inouye
patent: 5196317 (1993-03-01), Heinrich et al.
patent: 5294441 (1994-03-01), Curtiss, III
patent: 5316933 (1994-05-01), Yoshimatsu et al.
patent: 5387744 (1995-02-01), Curtiss, III
patent: 5468485 (1995-11-01), Curtiss, III
patent: 5656488 (1997-08-01), Curtiss, III
patent: 5672345 (1997-09-01), Curtiss, III
patent: 5681745 (1997-10-01), Szafranski et al.
patent: 5686580 (1997-11-01), Fasano et al.
patent: 5695983 (1997-12-01), Miller et al.
patent: 5702916 (1997-12-01), Molin et al.
patent: 5733760 (1998-03-01), Lu et al.
patent: 5747028 (1998-05-01), Calderwood et al.
patent: 5840483 (1998-11-01), Curtiss, III
patent: 5843426 (1998-12-01), Miller et al.
patent: 5843702 (1998-12-01), McConnell et al.
patent: 5855879 (1999-01-01), Curtiss, III
patent: 5855880 (1999-01-01), Curtiss et al.
patent: 6010901 (2000-01-01), Miller, III et al.
patent: 6024961 (2000-02-01), Curtiss, III et al.
patent: 6316609 (2001-11-01), Dillon et al.
patent: 6610529 (2003-08-01), Curtiss et al.
patent: 6780405 (2004-08-01), Curtiss et al.
patent: 2003/0082511 (2003-05-01), Brown et al.
patent: 2003/0157071 (2003-08-01), Wolfe et al.
patent: 0 381 706 (1995-04-01), None
patent: 1516458 (1976-09-01), None
patent: WO 95/14091 (1995-05-01), None
Curtiss et al, Immunological Investigations, Jan.-May 1989, vol. 18(1-4), pp. 583-589.
Cieslak, PR et al, Vaccine, vol. 11(7). pp. 773-776, 1993.
Gentry-Weeks, CR et al, Journal of Bacteriology, vol. 174(23), pp. 7729-7742, Dec. 1992.
Jagusztyn-Krynicka, EK et al, Mar. 1993, vol. 61(3), pp. 1004-1015.
Miller, IA et al, Mol. Gen. Genet, vol. 215, pp. 312-316, Jan. 1989.
Nakayama et al, Bio/Technology, vol. 6, pp. 693-697, 1988.
Schodel, F et al, Developments in biological standardization, vol. 82; pp. 151-158, 1994.
Schodel, F et al, Infection Immunity, May 1994, vol. 62(5), pp. 1669-1676.
Youderian, P et al, Virology, vol. 107(1), pp. 258-269, 1980.
Schodel, F e tal, Developments in biological standarizaiton, 1994, vol. 82, pp. 151-158 (abstract).
Redman, TK et al, Infection and Immunity, Aug. 1994, vol. 62(8), pp. 3162-3171 (abstract only).
Schodel, F et al, Infection and Immunity, May 1994, vol. 62(5), pp. 1669-1676 (abstract only).
Curtiss, R et al, Immunological investigations, Jan.-May 1989, vol. 18(1-4), pp. 583-596 (abstract only).
Curtiss III, R, Release of Genetically engineered microorganisms, Chapter 2, pp. 7-20, 1988, Engineering organisms for safely: what is necessary(query)-genetically engineered microorganism relase in the environment; recombinant vaccine construction.
Curtiss III, Roy, Genetic Manipulation of microorganisms: Potential benefits and biohazards, pp. 507-533, Ann. Rev. Microbiol. 1976, vol. 30, pp. 507-533.
Barrett,Textbook of Immunology, Fourth Edition (C.V. Mosby Co., St. Louis, MO 1983).
Bienkowska-Szewczyk et al., The R Gene Product of Bacteriophage λ.Mol. Gen. Genet.184:111-114 (1981).
Bochner et al., Positive Selection for Loss of Tetracycline Resistance,J. Bacteriol.143:926 (1980).
Cardenas and Clements, Oral Immunization Using Live AttenuatedSalmonellaspp. as Carriers of Foreign Antigens,Clinical Micro. Rev.5(31:328-342 (1992).
Cardineau and Curtiss, Nucleotide Sequence of the asd Gene ofStreptococcus mutans, J. Bio. Chem.262:33440-3353 (1987).
Chatfield et al., Construction of a Genetically DefinedSalmonella typhiMutant for the Engineering of a Candidate Oral Typhoid-Tetanus Vaccine,Vaccine10:53-80 (1992).
Chatfield et al., The Development of Oral Vaccines Based on Live AttenuatedSalmonellaStrains,FEMS lmmunol. Med. Microbiol.7:107 (1993).
Christie et al., Synthetic Sites for Transcription Termination and a Functional Comparison with Tryptophan Operon Termination Sites In Vitro,Proc. Natl. Acad. Sci. USA 78:4180-4184 (1981).
Clements, Use of Attenuated Mutants ofSalmonellaAs Carriers for Delivery of Heterologous Antigens to the Secretory Immune System,Pathol. Immunopathol. Res.6:137-146 (1987).
Contreras et al.,Appl. Microbiol. Biotechnol.57(5):1504-1508 (1991).
Cornelis, Yersiniae, Finely Tuned Pathogens,Molecular Biology of Bacterial Infections(Cambridge University Press, Cambridge, 1992).
Curtiss, Engineering Organisms for Safety: What is Necessary:The Release of Genetically-Engineered Micro-Organisms, M. Sussman, et al., editor, Academic Press, 7-20 (1988).
Curtiss, Genetic Manipulation of Microorganisms: Potential Benefits and Biohazards,Ann. Rev.30:507-533 (1976).
Curtiss et al., Research on Bacterial Conjugation with Mini-Cells and Minicell-ProducingE. ColiStrains,Microbial Drug Resistance 3:169-183 (1982).
Curtiss et al.,Salmonella typhimuriumDeletion Mutants Lacking Adenylate Cyclase and Cyclic AMP Receptor Protein Are avirulent and Immunogenic,Infect. Imm.553035-3043 (1987).
Curtiss et al., Chromosomal Aberrations Associated with Mutants to Bacteriophage Resistance inEscherichia Coli, J. Bacteriol.89:28-40 (1965).
Curtiss et al., AvirulentSalmonellaExpressing virulence Antigens from other Pathogens for use as Orally Administered Vaccines,Virulence Mechanisms of Bacterial Pathogens, (Roth, American Society for Microbiology, Washington, D.C. 1988) pp. 311-328.
Curtiss et al., RecombinantSalmonellaVectors in Vaccine Development,Dev. Biol. Stand.82:23-33 (1994).
Curtiss et al., Stable Recombinant AvirulentSalmonellaVaccine Strains,Adv. Exp. Med. Biol.251:33-47 (1989).
Curtiss, AttenuatedSalmonellaStrains as Live Vectors for the Expression of Foreign Antigens,New Generation Vaccines(Woodrow and Levine, eds. Marcel Dekker, New York, 1990) pp. 161-188.
Doggett and Curtiss Delivery of Antigens by Recombinant AvirulentSalmonellaStrains,Adv. Exp. Med. Biol.327:165-173 (1992).
Dorman et al., Characterization of Porin and ompR Mutants of a Virulent Strain ofSalmonella typhimurium: ompR Mutants are Attenuated in Vivo,Infect. Immun.57:2136-2140 (1989).
Dougan et al., Live OralSalmonellaVaccines: Potential Use of Attenuated Strains as Carriers of Heterologous Antigens to the Immune System,Parasite Immun.9:151-160 (1987).
Dul et al., Genetic Mapping of a Mutant Defective in D. L-Alanine Racemase inBacillus subtillis168,J. Bacteriol.115:1212 (1973).
Ferrari et al., Isolation of an Ala
Curtiss III Roy
Tinge Steven A.
Mondesi Robert B
Portner Ginny
Washington University
Wesolowski Michael R.
Yankwich Leon R.
LandOfFree
Recombinant bacterial vaccine system with environmentally... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant bacterial vaccine system with environmentally..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant bacterial vaccine system with environmentally... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2702098